Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 17/20 | 0.64 |
| ▸ | MC3R | P41968 | 7/20 | 0.62 |
| ▸ | MC5R | P33032 | 7/20 | 0.62 |
| ▸ | MC1R | Q01726 | 7/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.62 |
| ▸ | PRCP | P42785 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3170759 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL71984 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL71981 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL29904550 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL15252713 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL70497 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL30593923 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL1920391 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| Hydrochloric Acid SCHEMBL4939210 | 0.99 | MC4R (0.63) | MC4RMC3RMC5RMC1RKCNH2 | |
| Hydrochloric Acid SCHEMBL4939214 | 0.99 | MC4R (0.63) | MC4RMC3RMC5RMC1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129413-B2 | Crystalline forms of MC4R agonist and process for synthesis | MERCK SHARP & DOHME CORP. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090233967-A1 | Crystalline forms of mc4r agonist and process for synthesis | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-7329673-B2 | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7276520-B2 | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233967-A1 | Crystalline forms of mc4r agonist and process for synthesis | MC4R, MC3R, MC2R | MC4R 1/4885MC3R 2/4885MC5R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.